HIV
and AIDS Top News Articles |
|
 Excellent
Response with a PI- and NRTI-sparing Regimen of Raltegravir
(Isentress), Maraviroc (Selzentry), and Etravirine
(Intelence) - 11/14/2008 |
| Adherence,
Pharmacokinetics, and Metabolic Changes in Treatment-naive Patients Receiving
Once-daily or Twice-daily Lopinavir/ritonavir (Kaletra):
Study M05-730 - 11/14/2008 |
| Biomarkers
of Inflammation and Coagulation in Children and Adolescents
with HIV - 11/14/2008 |
 Rosuvastatin
(Crestor) Dramatically Lowers Cardiovascular Risk in Individuals with
Normal Cholesterol but Elevated CRP - 11/14/2008 |
 GlaxoSmithKline
Launches New Patient Assistance Program for
7 Antiretroviral Drugs or Coformulations -
11/14/2008 |
 Studies
Look at Long-term Safety of Tenofovir (Viread/Truvada/Atripla),
including Kidney Toxicity and Bone Loss -
11/11/2008 |
| Should
Antiretroviral Therapy Be Guided By Therapeutic Drug
Monitoring? - 11/11/2008 |
| Experimental
HIV Entry Inhibitor PRO 140 Demonstrates Favorable
Activity Phase 2 Trial - 11/11/2008
|
| Investigational
NNRTI RDEA806 Exhibits Promising Activity
and Has High Barrier to Resistance - 11/11/2008
|
| Race/ethnicity
and Income Impact HIV Treatment Access and Outcomes -
11/07/08 |
| Maraviroc
(Selzentry) Is Associated with Faster and Larger CD4 Cell Gains: MERIT
Trial - 11/07/08 |
| HIV
Positive People on HAART Have an Elevated Risk of Pulmonary
Hypertension - 11/07/08 |
| Experimental
NRTI Elvucitabine Suppresses HIV as Well as
Lamivudine at 48 Weeks - 11/07/08 |
| Risk
of Hospitalization Remains High for 3 Months after Starting HAART
- 11/04/08 |
| Lopinavir/ritonavir
(Kaletra) Monotherapy Produces Sustained HIV Suppression: IMANI-2 and
OK04 Studies - 11/04/08 |
| Fosamprenavir
(Lexiva) Is Equally Effective with a Lower 100 mg Ritonavir
(Norvir) Boosting Dose - 11/04/08 |
| Experimental
HIV Maturation Inhibitor Bevirimat Demonstrates
Good Antiviral Activity and Favorable Safety Profile -
11/04/08 |
 New
Updates to Adult and Adolescent Anti-HIV Treatment Guidelines
- 11/04/08-
11/04/08 |
| Is
HIV Becoming More Virulent? - 10/31/2008 |
| Abacavir/lamivudine
(Epzicom) plus Boosted Atazanavir (Reyataz) Provides Potent Antiviral
Activity at All Viral Load Levels in ARIES Trial; Meta-analysis Favors Tenofovir/emtricitabine
(Truvada) - 10/31/2008 |
| Boosted
Atazanavir (Reyataz) and Lopinavir/ritonavir (Kaletra) Are Both Highly
Effective through 96 Weeks, but Atazanavir Has Better Side Effects Profile: CASTLE
Study - 10/31/2008 |
| Darunavir
(Prezista) Is Safe and Effective in HIV Positive Children and Adolescents
at 48 Weeks: DELPHI Trial - 10/31/2008 |
| Continuous
HAART Associated with Elevated Risk of Bone Loss
in SMART Treatment Interruption Trial - 10/31/2008 |
 Starting
HAART with a CD4 Count of 351-500 Reduces Risk of Death
by 71% - 10/28/2008 |
 Raltegravir
(Isentress) Is as Effective as Efavirenz (Sustiva)
at 48 Weeks in Treatment-naive Patients: STARTMRK Trial
- 10/28/2008 |
 MERIT
Reanalysis with More Sensitive Trofile Test Shows Maraviroc
(Selzentry) Works as well as Efavirenz (Sustiva)
in Patients New to Therapy - 10/28/2008 |
| Long-term
Safety of Investigational CCR5 Antagonist Vicriviroc
in Treatment-experienced Patients - 10/28/2008 |
| Efficacy
and Safety of Boosted Darunavir (Prezista)
Are Comparable to Lopinavir/ritonavir (Kaletra)
at 96 Weeks: ARTEMIS Trial - 10/28/2008 |
 Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Begins this Weekend in Washington, DC -
10/24/08 |
 Darunavir
(Prezista) Receives Full Traditional Approval, Dose Set for Treatment-naive
Patients, Caution Urged for Pregnant Women -
10/24/08 |
 Inflammation
and Coagulation Biomarkers Linked to Higher Risk of Death in Patients
Who Interrupt Antiretroviral Therapy - 10/24/08 |
 Excess
Risk of Opportunistic Diseases and Death Remains
after Reinitiating HAART following Treatment Interruption -
10/24/08 |
| Study
Suggests HIV Could Rebound from a Single T-cell
if Antiretroviral Therapy Is Interrupted -
10/24/08 |
 Drug
Resistance Is More Likely with NNRTIs than with Boosted Protease Inhibitors
- 10/21/08
|
| Emergence
of Drug Resistance Is Associated with Treatment
Failure -
10/21/08 |
 Lowest-ever
CD4 Cell Count Predicts Neurocognitive Impairment
in People with HIV -
10/21/08 |
 Cancer
and Long-term Toxicities in Children Exposed to Antiretroviral Drugs
before Birth -
10/21/08 |
 Researchers
Identify Proteins Associated with Resistance to HIV
Infection in Kenyan Sex Workers -
10/21/08 |
 Small
Decreases in HIV Viral Load Can Reduce Disease Progression,
Transmission
- 10/17/08 |
 Strength
Training Improves Insulin Sensitivity and Reduces Body Fat in HIV
Positive Patients with Lipodystrophy
- 10/17/08 |
 Ezetimibe
(Zetia) Reduces Bad LDL Cholesterol in HIV Positive People on HAART
-
10/17/08 |
 Structure
of Natural Anti-HIV Protein APOBEC-3G Discovered
-
10/17/08 |
 Study
Finds 3 Million Injection Drug Users -- about 1 in 5 -- Are HIV
Positive Worldwide - 10/17/08 |
 October
15 is National Latino AIDS Awareness Day;
Study Looks at HIV/AIDS in U.S. Hispanic/Latino Population -
10/14/08 |
| Low
Doses of CCR5 Antagonist Vicriviroc Do Not
Suppress HIV as well as Efavirenz (Sustiva)
in Treatment-naive Patients; New Study Underway -
10/14/08 |
 Tenofovir
(Viread) Associated with Mild Kidney Function Impairment, but not Clinically
Relevant Renal Disease -
10/14/08 |
 Treatment
Interruption Can Lead to Higher Risk of HIV Transmission -
10/14/08 |
 Studies
Indicate that Circumcision Provides Minimal
Protection against HIV Infection in Men who have Sex with Men -
10/14/08 |
 Immune
Suppression Predicts Non-AIDS-related as well as AIDS-defining Malignancies
in People with HIV - 10/10/08 |
 Lower
CD4 Count Linked to Increased Risk of Liver Cancer in
HIV Positive People, Especially Those with Hepatitis B Coinfection
-
10/10/08 |
 HLA-B*5701
Screening for Abacavir Hypersensitivity -
10/10/08 |
 Individual
Genetic Variations, Rather than Race/Ethnicity, Best Predict Efavirenz
(Sustiva) Side Effects -
10/10/08 |
 HIV/AIDS
Researchers Win Nobel and MacArthur Prizes
- 10/10/08
|
 CDC
Updates Estimates of HIV Prevalence in the
United States - 10/07/08 |
| Tenofovir
(Viread) Administered Orally, by Injection, or as a Rectal Microbicide
Protects Monkeys from Infection with HIV-like Virus -
10/07/08 |
 Mathematical
Model Shows PrEP Could be Cost-effective for
Men Who Have Sex with Men - 10/07/08 |
 PrEP
using Tenofovir plus Emtricitabine May Offer Benefits even if HIV Infection
Occurs - 10/07/08 |
 Influenza
Vaccines Now Available for Upcoming Flu Season -
10/07/08 |
 Boosted
Atazanavir (Reyataz) Approved for Treatment-naive HIV Patients
- 10/03/08 |
| CCR5
Antagonist Maraviroc (Selzentry) Suppresses HIV in Treatment-experienced
Patients with Drug-resistant Virus - 10/03/08 |
 Didanosine
(Videx EC) Product Label Updated with New Dosing Recommendations for
HIV Positive Children - 10/03/08 |
| Lack
of HAART and Low CD4 Cell Count are Linked to Non-AIDS-related as well
as Opportunistic Conditions - 10/03/08 |
 New
Findings Indicate HIV Began Spreading among Humans
Earlier than Previously Thought - 10/03/08
|
 How
Safe is HIV Serosorting for Men who have Sex with Men?
- 10/03/08 |
 U.S.
Eases Visa Restrictions for HIV Positive Visitors
- 10/03/08 |
 Drug
Resistance, CD4 Response, and Progression to AIDS and Death in Patients
Who Delay Switching Compared with Those Who Switch Rapidly after Treatment
Failure - 9/25/08 |
 Viral
Load Rebound and CD4 Cell Declines following Treatment Interruption
Are Less Pronounced in Individuals with Primary HIV Infection -
9/25/08 |
 Blood
Lipid Profiles Improve after CD4-guided Treatment Interruption
- 9/25/08 |
 Zidovudine
(Retrovir) Product Label Updated with New Dosing Recommendations for
Children with HIV -
9/25/08 |
 HIV
Positive Tuberculosis Patients Need to Start Antiretroviral Treatment
Early - 9/25/08 |
| Circumcision
May Prevent HIV Infection in Older Men -- and Some Gay Men -- but Complications
Are Common in Resource-limited Settings |
| Contemporary
Once-daily Fixed-dose Antiretroviral Regimens
Are More Durable than Earlier Treatment Options for HIV Patients -
9/23/08 |
 Antiretroviral
Therapy during Pregnancy Significantly Reduces Mother-to-child
HIV Transmission, but is Linked to Low Birth Weight -
9/23/08 |
| Phase
1 Trial of HIV Maturation Inhibitor Vivecon (MPC-9055)
Completed in Healthy Volunteers - 9/23/08 |
 Prevalence
of and Risk Factors for Methicillin-resistant
Staphylococcus aureus
(MRSA) in HIV Patients - 9/23/08 |
 CDC
Report Shows High HIV Rates among Blacks and Men Who Have Sex with
Men - 9/23/08 |
 Antiretroviral
Therapy May Be More Effective in People Who Become Infected with HIV
at an Older Age - 9/19/08 |
 Once-daily
Boosted Darunavir (Prezista) in Treatment-experienced Patients with
No Baseline Darunavir Resistance-associated Mutations -
9/19/08 |
 FDA
Issues Warning Letters, Bans Imports of Generic Drugs Produced by Indian
Company Ranbaxy - 9/19/08 |
 Switching
from Protease Inhibitors to NNRTIs Is a Potential Risk Factor for Kaposi
Sarcoma Relapse - 9/19/08 |
 People
with HIV May Have an Elevated Risk of Bone Fractures
- 9/19/08 |
Long-term Safety and Effectiveness of Growth
Hormone Releasing Factor Tesamorelin for Lipodystrophy
- 9/15/08 |
|
Genetic
Factors May Influence Fat Loss and Accumulation in People with HIV
- 9/15/08
|
Experimental
Fusion Inhibitor TRI-1144 May Permit Less Frequent Dosing and Cause
Fewer Injection Site Reactions than Enfuvirtide (Fuzeon)
- 9/15/08 |
|
FDA
Approves Immune Globulin Therapy for Difficult-to-treat Chronic Inflammatory
Demyelinating Polyneuropathy
- 9/15/08 |
Herpes
Viruses Change Acyclovir to a Form that Inhibits
HIV Replication
- 9/15/08 |
Sexual
Activities Other than Intercourse Carry a Risk of HIV and Other Sexually
Transmitted Infections
- 9/15/08 |
|
Despite HAART, People with HIV Are Still At
Risk for Life-threatening Progressive Multifocal Leukoencephalopathy
(PML) -
9/12/2008 |
|
Cidofovir
(Vistide) in Addition to Antiretroviral Therapy Is Not Effective for
AIDS-related Progressive Multifocal Leukoencephalopathy
(PML) -
9/12/2008 |
|
Time
to Virological Failure with Boosted Atazanavir (Reyataz)
or Lopinavir/ritonavir (Kaletra) Is Not Affected by Use of H2 Receptor
Blockers -
9/12/2008 |
Effect
of Lopinavir/ritonavir (Kaletra) Monotherapy
on Symptoms and Quality of Life -
9/12/2008 |
Boosted
Tipranavir (Aptivus) Is Cost-effective in Treatment-experienced HIV
Patients in the U.S. -
9/12/2008 |
Experimental
NNRTI IDX899 Exhibits Good Antiviral Activity in 7-day Phase I/II Clinical
Trial -
9/12/2008 |
| Recommendations
for Treatment-experienced HIV Patients on Failing Regimens Containing Boosted
Darunavir (Prezista/r) - 9/09/2008 |
 HAART
Reduces Likelihood of Syphilis Treatment Failure
in People with HIV -
9/09/2008 |
| SMART
Researchers Publish Findings Showing Abacavir (Ziagen)
Is Associated with Elevated Risk of Cardiovascular Disease -
9/09/2008 |
 Apobec3
Gene Might Stimulate Production of Antibodies that Neutralize HIV -
9/09/2008 |
| Management
of Elevated Blood Lipids May Be Less Successful in HIV Patients with High
Cardiovascular Risk -
9/09/2008 |
| FDA
Warns of Potential Problems with Certain Prescription Drugs -
9/09/2008 |
|
FDA-approved
Treatments
